Current approaches to the treatment of Alzheimer's disease

Neurodegeneration

Volumn 5, Issue 4, 1996, Pages 505-509

  Wilcock, Gordon K ^a  

^a FRENCHAY HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; Therapy; Treatment

Indexed keywords

AMYLOID PROTEIN; ANTIINFLAMMATORY AGENT; CHOLINESTERASE INHIBITOR; NEUROTRANSMITTER; NICOTINE;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; CONFERENCE PAPER; HUMAN; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; PRIORITY JOURNAL;

EID: 0030512146     PISSN: 10558330     EISSN: None     Source Type: Journal    
DOI: 10.1006/neur.1996.0070     Document Type: Conference Paper

References (24)

1. Agnoli A, Fabbrini G, Fioravanti S, Martucci N (1992) CBF and cognitive evaluation of Alzhimer type patients before and after IMAO-B treatment: a pilot study. Fur Neuropsychopharmacol 2:31-35
2. Blennow K, Wallin A, Gottfries CG, Lekman A, Karllson I, Skoog I, Svennerholm L (1992) Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease. Neurobiol Aging 12:581-587
3. Davis KL, Mohs RC, Tinklenberg JR (1979) Enhancement of memory by physostigmine [letter]. N Engl J Med 301:946
4. van-Duijn CM, Hofman A (1991) Relation between nicotine intake and Alzheimer's disease. Br Med J 302:1491-1494
5. Elble RJ, Giacobini E, Becker R (1988) Treatment of Alzheimer dementia with steady-state infusion of physostigmine. In Giacobini E, Becker R, eds. Current research in Alzheimer therapy: cholinesterase inhibitors. New York: Taylor & Francis: 123-139
6. Finali G, Piccinilli M, Oliani C, Piccinin GL (1991) L-deprenyl therapy improves verbal memory in amnesic Alzheimer's patients. Clin Neuropharmacol 14:523-536
7. Friden PM, Walus LR, Watson P (1993) Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science 259:373-377
8. Goad DL, Davis CM, Liem P, Fuselier C, McCormack JR, Olsen KM (1991) The use of selegiline in Alzheimer's patients with behavioural problems. J Clin Psychiatry 52:342-345
9. Gustafson L (1993) Physostigmine and tetrahydroaminoacridine in Alzheimer's disease. Acta Neurol Scand Suppl 149:39-41
10. Hagg T, Fass-Holmes B, Vahlsing HL, Manthorpe M, Conner JM, Varon S (1989) Nerve growth factor (NGF) reverses axotomy-induced decreases in choline acetyltransferase, NGF receptor and size of medial septum cholinergic neurons. Brain Res 505:29-38
11. Hagg T, Manthorpe M, Vahlsing HL, Varon S (1988) Delayed treatment with nerve growth factor reverses the apparent loss of cholinergic neurons after acute brain damage. Exp Neurol 101:303-312
12. Johns CA, Hartoutunian V, Greenwald BS (1985) Development of cholinergic drugs for the treatment of Alzheimer's disease. Drug Dev Res 5:77-96
13. Knapp JM, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI (1994) A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 271:985-991
14. Lee PN (1994). Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology 13:131-144
15. Levy A, Brandeis R, Treves T, Mesulam Y, Mawassi F, Feiler D, Wengier A, Glikfeld P, Grunwald J, Dachir S (1994) Transdermal physostigmine in the treatment of Alzheimer's disease. Alzheimer Dis Assoc Disord 8:15-21
16. Nazarali AJ, Reynolds GP (1992) Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: a postmortem study. Cell Mol Neurobiol 12:581-587
17. Peters BH, Levin HS (1982) Chronic oral physostigmine and lecithin administration in memory disorders of aging. In Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ, eds. Alzheimer's disease: a report of progress in research. Aging, vol 19, New York: Raven Press, 361-367
18. 3H]idazoxan binding sites (12 imidazoline sites) are increased in postmortem brains from patients with Alzheimer's disease. Neurosci Lett 160:109-112
19. Sano M, Bell K, Marder K, Stricks D, Stern Y, Mayeux R (1993) Safety and efficacy of oral physostigmine in the treatment of Alzheimer's disease. Clin Neuropharmacol 16: 61-69
20. Sherif F, Gottfries CG, Alafuzoff I, Oreland L (1992) Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer's disease. J Neural Transm Park Dis Dement Sect 4:227-240
21. Stern Y, Sano M, Mayeux R (1988) Long-term administration of oral physostigmine in Alzheimer's disease. Neurology 38:1837-1841
22. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A (1986) Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 315: 1241-1245
23. Tuszynski MH, Roberts J, Senut M-C, U H-S, Gage FH (1996) Gene therapy in the adult primate brain. Intraparenchymal grafts of cells genetically modified to produce nerve growth factor to prevent cholinergic neuronal degeneration. Gene Therapy 3:305-314
24. Tuszynski MH, U H-S, Amaral DG, Gage FH (1990) Nerve growth factor infusion in the primate brain reduces lesion-induced cholinergic neuronal degeneration. J Neurosci 10:3604-3614